$679 Million is the total value of Foresite Capital Management IV, LLC's 12 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KNTE | Kinnate Biopharma Inc. | $222,641,000 | -1.1% | 9,671,643 | 0.0% | 32.78% | +7.7% | |
| LYEL | Lyell Immunopharma, Inc. | $196,576,000 | -8.9% | 13,282,181 | 0.0% | 28.95% | -0.7% | |
| ACRS | Aclaris Therapeutics, Inc. | $61,183,000 | +2.5% | 3,399,034 | 0.0% | 9.01% | +11.7% | |
| PHVS | Pharvaris N.V. | $57,834,000 | -4.8% | 3,261,926 | 0.0% | 8.52% | +3.7% | |
| QSI | Quantum-Si Incorporated | $37,227,000 | -32.0% | 4,463,619 | 0.0% | 5.48% | -25.9% | |
| NRIX | Nurix Therapeutics, Inc. | $36,126,000 | +12.9% | 1,205,798 | 0.0% | 5.32% | +23.0% | |
| KURA | Kura Oncology, Inc. | $34,650,000 | -10.2% | 1,849,947 | 0.0% | 5.10% | -2.1% | |
| New | Cue Health Inc. | $11,882,000 | – | 1,006,089 | +100.0% | 1.75% | – | |
| OLMA | Olema Pharmaceuticals, Inc. | $9,426,000 | -1.5% | 342,030 | 0.0% | 1.39% | +7.3% | |
| CBAY | Cymabay Therapeutics, Inc. | $6,523,000 | -16.3% | 1,787,094 | 0.0% | 0.96% | -8.7% | |
| TPST | Buy | Tempest Therapeutics, Inc. | $2,752,000 | +29.4% | 190,213 | +0.0% | 0.40% | +40.6% |
| DBTX | Decibel Therapeutics, Inc. | $2,295,000 | -10.4% | 297,711 | 0.0% | 0.34% | -2.3% | |
| CYTK | Exit | Cytokinetics Incorporated | $0 | – | -545,101 | -100.0% | -1.46% | – |
| RLAY | Exit | Relay Therapeutics, Inc. | $0 | – | -556,380 | -100.0% | -2.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
| Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
| Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
| Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
| Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
| Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
| Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
| Insmed Incorporated | 10 | Q1 2020 | 19.2% |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-02-22 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.